Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Neurosense Therapeutics Ltd. ( (NRSN) ) has issued an update.
On October 6, 2025, NeuroSense Therapeutics Ltd. announced that its drug candidate PrimeC demonstrated statistically significant reductions in Alzheimer’s disease biomarkers in its Phase-2b PARADIGM study. These findings suggest that PrimeC can effectively target biological pathways central to Alzheimer’s disease progression, potentially offering a disease-modifying therapy. The results are promising for NeuroSense’s positioning in the biotechnology industry, as they plan to use these findings to inform future Alzheimer’s disease studies and advance PrimeC’s readiness program for ALS.
The most recent analyst rating on (NRSN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Underperform.
Neurosense Therapeutics Ltd. faces substantial financial difficulties, including no revenue and negative equity, severely impacting its overall score. Technical indicators are neutral but do not offset financial weaknesses. The valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Parkinson’s disease. The company aims to address significant unmet medical needs by developing combined therapies targeting multiple pathways associated with these complex diseases.
Average Trading Volume: 638,270
Technical Sentiment Signal: Sell
Current Market Cap: $30.75M
See more insights into NRSN stock on TipRanks’ Stock Analysis page.